医学
内科学
肝细胞癌
阿替唑单抗
伦瓦提尼
贝伐单抗
倾向得分匹配
经导管动脉化疗栓塞
胃肠病学
置信区间
不利影响
阶段(地层学)
危险系数
肿瘤科
癌症
化疗
索拉非尼
无容量
古生物学
免疫疗法
生物
作者
Takashi Niizeki,Seiichi Mawatari,Michihiko Shibata,Ryu Sasaki,Shinji Itoh,Satoshi Shakado,Rie Sugimoto,Yusuke Morita,Takuya Kuwashiro,Mizuki Endo,Masao Iwao,Yasuhide Motoyoshi,Masahito Nakano,Shigeo Shimose,Hirokazu Takahashi,Hiroshi Yatsuhashi,Fumihito Hirai,Tomoharu Yoshizumi,Hisamitsu Miyaaki,Takumi Kawaguchi
摘要
ABSTRACT Background and Aim This study aimed to compare the therapeutic effects and safety of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN‐TACE) and atezolizumab plus bevacizumab (Atez/Bev) as the first‐line therapies in patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond the up‐to‐seven criteria. Methods We enrolled 768 patients with HCC treated with first‐line systemic therapy, and 154 patients were enrolled and categorized into either the LEN‐TACE therapy ( n = 42) or Atez/Bev ( n = 112) groups. After propensity score matching (PSM), 72 patients (LEN‐TACE group, n = 36; Atez/Bev group, n = 36) were analyzed. Results After PSM, the median progression‐free survival showed no significant differences between the LEN‐TACE and Atez/Bev groups (8.5 [95% confidence interval (CI): 6.1–10.7] months vs. 8.6 (95% CI: 5.3–12.1) months, respectively; p = 0.973). Regarding median overall survival (OS), no significant differences were noted between the LEN‐TACE and Atez/Bev groups (37.3 [95% CI: 31.2–60.2] months vs. 32.4 (95% CI: 19.5–NE) months, respectively; p = 0.183). Regarding adverse events (AEs) of grade ≥ 3, no significant difference was observed between the two groups. Multivariate analysis revealed that the ALBI grade 1 and low AFP levels were independent factors for OS. Conclusion LEN‐TACE therapy may be one of the effective treatment strategies in intermediate‐stage HCC patients beyond the up‐to‐seven criteria.
科研通智能强力驱动
Strongly Powered by AbleSci AI